

Special Issue

Advances in miRNA Research

Message from the Guest Editor

In recent years, substantial progress has been made in studying the role of microRNAs (miRNAs) in the pathogenesis of diseases. Numerous studies have shown that these short RNA sequences play a crucial role in the neoplastic process, including cell-death regulation, proliferation, signalling, and the formation of metastasis. Increasing evidence has revealed the deregulation of miRNA levels in cancer and negative regulation of gene and protein expression by acting as oncogenes or tumor suppressors. This Special Issue invites original papers and reviews covering a wide range of topics related to miRNAs, such as miRNA-activated functional networks, miRNA expression regulation, miRNA therapeutics, miRNA function as biomarkers, and the role of miRNA in cancer drug resistance in various kinds of cancers.

Guest Editor

Dr. Dragoş Creţoiu

Discipline of Medical Genetics, Department of Pediatrics, Faculty of Medicine, Carol Davila University of Medicine and Pharmacy, Bucharest, Romania

Deadline for manuscript submissions

closed (20 August 2023)

G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



mdpi.com/si/149545

Genes
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
genes@mdpi.com

[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



G C A T
T A C G
G C A T

Genes

an Open Access Journal
by MDPI

Impact Factor 2.8
CiteScore 5.5
Indexed in PubMed



[mdpi.com/journal/
genes](https://mdpi.com/journal/genes)



About the Journal

Message from the Editor-in-Chief

Genes is central to our understanding of biology, and modern advances such as genomics and genome editing have maintained genetics as a vibrant, diverse and fast-moving field. There is a need for good quality, open access journals in this area, and the *Genes* team aims to provide expert manuscript handling, serious peer review, and rapid publication across the whole discipline of genetics. Starting in 2010, the journal is now well established and recognised. Why not consider *Genes* for your next genetics paper?

Editor-in-Chief

Prof. Dr. Selvarangan Ponnazhagan
Experimental Cancer Therapeutics, The University of Alabama at
Birmingham, 1825 University Blvd., SHEL 814, Birmingham, AL 35294-
2182, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Genetics and Heredity) / CiteScore - Q2 (Genetics (clinical))